Assess the role of interleukins in the pathogenesis of IBD and the potential therapeutic implications of targeting IL-23 and CD64 in IBD Evaluate the safety/efficacy data and mechanisms of action of available and emerging IL inhibitors for the treatment of IBD, with a focus on agents targeting IL-23
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership · $99–598/yr
| New Membership – Standard | $349/yr |
| New Membership – Standard (2-year) | $598/yr |
| New Membership – Military/VA | $259/yr |
| New Membership – Student/Resident | $149/yr |
| Renewal Membership – Standard | $249/yr |
| Renewal Membership – Standard (2-year) | $478/yr |
+27 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- General & Adult Psychiatry
- General Surgery
- Interventional Radiology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Nuclear Medicine
- Pain Medicine
- Pediatric Neurology
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Sleep Medicine
- Cross-Specialty
- Medical Subspecialties
- Neurology
- Pain & Palliative
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 0.75 credits
- MOC · Up to 0.75 points
- Commercial Support
-
ReleasedOct 15, 2025
-
Last day to claim creditOct 16, 2026 4 days left
-
HMP Education Novel Strategies to Advance IBD Care: A Focus on the Role of IL-23 Inhibitors for the Management of Crohn s Disease and Ulcerative Colitis
-
HMP Education Targeting TNF in IBD: Innovations in Drug Design, Delivery, and Clinical Application
-
HMP Education From Inflammation to Individualization: Advances in Precision Medicine and Novel Anti-TL1A Therapies for Inflammatory Bowel Dise
-
Answers in CME Inc. (AiCME) Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer
-
Paradigm Medical Communications, LLC The Science and Art of Retina: Exploring the Role of Ang-2 and VEGF Inhibition Across Common Clinical Scenarios
-
Med-IQ The Future Potential of Factor XI/XIa Inhibitors to Address Stroke Risk in AF
